Partnership Seeks to Accelerate Development of Innovative Therapies
Approval marks first oral therapy for MCL patients, and a new option for patients with unmet medical need
Anti-CD20-Interferon Alpha Fusion Protein is a promising therapy for NHL patients resistant to standard therapy